In the largest study to date evaluating outcomes of Hispanic women with endometrial uterine cancer, researchers at the University of Texas Medical Branch at Galveston have found that Hispanic women in the ...
Dec 16, 2014
5 / 5 (3) | 0
U.S. regulators on Friday granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from British drugmaker AstraZeneca PLC.
1 hour ago
4 / 5 (1) | 0